Dose-ranging study of the angiotensin II receptor antagonist irbesartan (SR 47436/BMS-186295) on blood pressure and neurohormonal effects in salt-deplete men

What Was Tested

This randomized controlled trial paper looks at Angiotensin II in the context of low blood pressure and orthostatic hypotension.

The researchers characterised the blood pressure (BP) and hormonal responses to the oral angiotensin II (Ang II) receptor antagonist irbesartan (SR47436/BMS-186295) or placebo in normal men with an activated renin-angiotensin system (RAS) during salt depletion.

The researchers also evaluated safety and tolerability.

Who Took Part

PubMed indexes the participants as adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Supine and erect BP and heart rate (HR), serum and urinary electrolytes: plasma renin activity (PRA), and Ang II were measured at intervals.

What Was Measured

The researchers also evaluated safety and tolerability.

The subject headings attached to it are Angiotensin II, Angiotensin Receptor Antagonists, Biphenyl Compounds, Blood Pressure, Diet, Sodium-Restricted, Heart Rate and Irbesartan.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension.

The publication is from 1996 (Journal of cardiovascular pharmacology), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.